THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

In August, the agency warned that many people are overdosing on alternatives to Ozempic and Wegovy due to the do-it-yourself ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Danish pharma giant Novo Nordisk has said it is aware of at least 10 deaths and 100 hospitalisations linked to compounded versions of semaglutide -- the active ingredient in popular diabetes and ...

The costs for 806 patients with overweight or obesity and heart failure were analyzed in one study. For those patients, the average total medical costs dropped from $29,654 before treatment began to ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...